The upgraded facilities bolster the company’s ability to conduct advanced in vitro assays, including testing in human whole blood, peripheral blood mononuclear cells, and specialized antigen-presenting cells like dendritic cells. By integrating these physical capabilities with its existing ISPRI in silico toolkit, EpiVax aims to provide developers with a comprehensive, multidimensional risk assessment platform that operates from early discovery through to clinical commercialization.
In section Releases
EpiVax Doubles Lab Capacity to Advance Human-Relevant Immunogenicity Testing
EpiVax has more than doubled its laboratory footprint at its Providence, Rhode Island headquarters, a move designed to meet the rising industry demand for non-animal, human-relevant testing methodologies. This expansion enables the company to scale its integrated approach to evaluating immunogenicity risks for biologics and emerging therapeutic modalities.
Global regulatory bodies are increasingly prioritizing new approach methodologies (NAMs) over traditional animal models, which often fail to mirror human immune responses. EpiVax has already utilized its PANDA screening framework to support over 16 successful regulatory submissions, proving that combining computational screening with targeted laboratory assays can effectively characterize immune activation before clinical exposure. According to Vibha Jawa, Ph.D., the company's Chief Scientific Officer, this physical expansion streamlines workflows and allows partners to make more precise, data-driven decisions throughout the product development lifecycle.
Comments (0)
No comments yet. Be the first!